within Pharmacolibrary.Drugs.ATC.L;

model L02AE01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 0.018166666666666668,
    adminDuration  = 600,
    adminMass      = 0.0005,
    adminCount     = 1,
    Vd             = 0.0202,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Buserelin is a synthetic analogue of the gonadotropin-releasing hormone (GnRH) used primarily in the treatment of hormone-sensitive cancers such as prostate cancer, endometriosis, and occasionally in assisted reproduction. It acts as a GnRH agonist, causing downregulation of pituitary secretion of gonadotropins and subsequent reduction in sex steroid production. The drug is approved and in current clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy male volunteers after single subcutaneous administration.</p><h4>References</h4><ol><li><p>Blom, JH, et al., &amp; Krauss, B (1989). Pharmacokinetics and endocrine effects of the LHR analogue buserelin after subcutaneous implantation of a slow release preparation in prostatic cancer patients. <i>Urological research</i> 17(1) 43–46. DOI:<a href=&quot;https://doi.org/10.1007/BF00261050&quot;>10.1007/BF00261050</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2493705/&quot;>https://pubmed.ncbi.nlm.nih.gov/2493705</a></p></li><li><p>Fraser, HM (1993). GnRH analogues for contraception. <i>British medical bulletin</i> 49(1) 62–72. DOI:<a href=&quot;https://doi.org/10.1093/oxfordjournals.bmb.a072606&quot;>10.1093/oxfordjournals.bmb.a072606</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8324616/&quot;>https://pubmed.ncbi.nlm.nih.gov/8324616</a></p></li><li><p>Holland, FJ, et al., &amp; Leeder, S (1986). Pharmacokinetic characteristics of the gonadotropin-releasing hormone analog D-Ser(TBU)-6EA-10luteinizing hormone-releasing hormone (buserelin) after subcutaneous and intranasal administration in children with central precocious puberty. <i>The Journal of clinical endocrinology and metabolism</i> 63(5) 1065–1070. DOI:<a href=&quot;https://doi.org/10.1210/jcem-63-5-1065&quot;>10.1210/jcem-63-5-1065</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3093518/&quot;>https://pubmed.ncbi.nlm.nih.gov/3093518</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L02AE01;
